PMID- 24723147
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20211021
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 14
IP  - 2
DP  - 2014 Jun
TI  - Effect of rivastigmine on mobility of patients with higher-level gait disorder: a 
      pilot exploratory study.
PG  - 57-62
LID - 10.1007/s40268-014-0038-8 [doi]
AB  - BACKGROUND: Higher-level gait disorder (HLGD) in older adults is characterized by 
      postural instability, stepping dysrhythmicity, recurrent falls and progressive 
      immobility. Cognitive impairments are frequently associated with HLGD. 
      OBJECTIVES: The aim of this study was to compare gait and cognitive performance 
      before and after the use of rivastigmine in patients with HLGD, free from 
      cognitive impairment or Parkinsonism. METHODS: Fifteen non-demented patients with 
      HLGD (age 79.2 +/- 5.9 years; 11 women; Mini-Mental State Examination [MMSE] 28.3 +/- 
      1.4) received escalating doses of rivastigmine for 12 weeks in an open-label, 
      pilot study. They were assessed before and after treatment (week 0 and week 12), 
      and after a 4-week washout period (week 16). Assessments included the Mindstreams 
      computerized neuropsychological battery, Activities-specific Balance Confidence 
      Scale, State-Trait Anxiety Inventory, Geriatric Depression Scale, Timed Up and Go 
      (TUG) test, gait speed and stride time variability. One-way multiple analysis of 
      variance tests for repeated measures were used, and Pillai's trace test was 
      considered as robust to investigate significant differences. RESULTS: The mean 
      dose of rivastigmine during the 8-12 week period was 5.1 +/- 2.3 mg/day. A positive 
      effect was observed on the Mindstreams memory subscale and anxiety scores 
      [Pillai's trace: F(6,724) = 0.508, p = 0.010; and F(7,792) = 0.545, p = 0.006, 
      respectively, over the course of the study] as well as on mobility (TUG test) 
      [Pillai's trace: F(4,863) = 0.448; p = 0.028], whereas gait speed and stride time 
      variability did not change. CONCLUSIONS: The use of relatively low-dose 
      rivastigmine did not affect gait speed and stride time variability; however, the 
      general mobility and anxiety were improved. These preliminary results warrant a 
      larger, randomized, placebo-controlled study.
FAU - Gurevich, Tanya
AU  - Gurevich T
AD  - Movement Disorders Unit, Department of Neurology, Tel Aviv Medical Center, 6 
      Weizman Street, Tel Aviv, 64239, Israel, tanyag@tlvmc.gov.il.
FAU - Balash, Yacov
AU  - Balash Y
FAU - Merims, Doron
AU  - Merims D
FAU - Peretz, Chava
AU  - Peretz C
FAU - Herman, Talia
AU  - Herman T
FAU - Hausdorff, Jeffrey M
AU  - Hausdorff JM
FAU - Giladi, Nir
AU  - Giladi N
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Phenylcarbamates)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Gait Disorders, Neurologic/*drug therapy
MH  - Humans
MH  - Neuroprotective Agents/administration & dosage/*therapeutic use
MH  - Phenylcarbamates/administration & dosage/*therapeutic use
MH  - Pilot Projects
MH  - Rivastigmine
PMC - PMC4070456
EDAT- 2014/04/12 06:00
MHDA- 2015/04/17 06:00
PMCR- 2014/04/11
CRDT- 2014/04/12 06:00
PHST- 2014/04/12 06:00 [entrez]
PHST- 2014/04/12 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
PHST- 2014/04/11 00:00 [pmc-release]
AID - 38 [pii]
AID - 10.1007/s40268-014-0038-8 [doi]
PST - ppublish
SO  - Drugs R D. 2014 Jun;14(2):57-62. doi: 10.1007/s40268-014-0038-8.